Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, Berd D, Mastrangelo MJ, Sato T.

J Vasc Interv Radiol. 2015 Apr;26(4):523-32.e2. doi: 10.1016/j.jvir.2014.11.037. Epub 2015 Feb 9.

2.

A tale of two pities: autologous melanoma vaccines on the brink.

Berd D.

Hum Vaccin Immunother. 2012 Aug;8(8):1146-51. doi: 10.4161/hv.20923. Epub 2012 Aug 1. Review.

3.

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma.

Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T.

Cancer Immunol Immunother. 2012 Feb;61(2):145-155. doi: 10.1007/s00262-011-1084-5. Epub 2011 Aug 19.

PMID:
21853302
4.

Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.

Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ.

J Surg Oncol. 2012 Jan;105(1):15-20. doi: 10.1002/jso.22051. Epub 2011 Aug 3.

PMID:
21815149
5.

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T.

Cancer Immunol Immunother. 2011 Jul;60(7):1039-45. doi: 10.1007/s00262-011-1019-1. Epub 2011 Apr 26.

PMID:
21519827
6.

High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T.

Radiology. 2009 Jul;252(1):290-8. doi: 10.1148/radiol.2521081252.

PMID:
19561263
7.

Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential.

Terai M, Tamura Y, Alexeev V, Ohtsuka E, Berd D, Mastrangelo MJ, Sato T.

Cancer Immunol Immunother. 2009 Aug;58(8):1307-17. doi: 10.1007/s00262-008-0644-9. Epub 2009 Jan 14.

PMID:
19142637
8.

Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL.

J Clin Oncol. 2008 Nov 20;26(33):5436-42. doi: 10.1200/JCO.2008.16.0705. Epub 2008 Oct 6.

PMID:
18838710
9.
10.

Whipsaw cancer treatments: the role of hormesis in endocrine and immune therapies.

Prehn RT, Berd D.

Semin Oncol. 2006 Dec;33(6):708-10. Review.

PMID:
17145351
11.

Calculation of survival of patients with stage III melanoma.

Berd D, Mastrangelo MJ, Sato T.

J Clin Oncol. 2005 Dec 20;23(36):9427; author reply 9428. No abstract available.

PMID:
16361644
12.

Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.

Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T.

Melanoma Res. 2005 Aug;15(4):297-304.

PMID:
16034309
13.

M-Vax: an autologous, hapten-modified vaccine for human cancer.

Berd D.

Expert Rev Vaccines. 2004 Oct;3(5):521-7. Review.

PMID:
15485331
14.

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ.

J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.

PMID:
14691123
15.

Acute extracellular acidification reduces intracellular pH, 42 degrees C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7.

Coss RA, Storck CW, Wachsberger PR, Reilly J, Leeper DB, Berd D, Wahl ML.

Int J Hyperthermia. 2004 Feb;20(1):93-106.

PMID:
14612316
16.

Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy.

Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K.

Cancer Immunol Immunother. 2004 Jan;53(1):53-61. Epub 2003 Sep 10.

PMID:
13680192
17.

Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells.

Coss RA, Storck CW, Daskalakis C, Berd D, Wahl ML.

Mol Cancer Ther. 2003 Apr;2(4):383-8.

18.
19.

Regulation of intracellular pH in human melanoma: potential therapeutic implications.

Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS.

Mol Cancer Ther. 2002 Jun;1(8):617-28.

20.

Acute extracellular acidification increases nuclear associated protein levels in human melanoma cells during 42 degrees C hyperthermia and enhances cell killing.

Han JS, Storck CW, Wachsberger PR, Leeper DB, Berd D, Wahl ML, Coss RA.

Int J Hyperthermia. 2002 Sep-Oct;18(5):404-15.

PMID:
12227927
21.
22.

Is human aging still mysterious enough to be left only to scientists?

de Grey AD, Baynes JW, Berd D, Heward CB, Pawelec G, Stock G.

Bioessays. 2002 Jul;24(7):667-76.

PMID:
12111727
23.

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

Berd D, Sato T, Mastrangelo MJ.

Cancer Immunol Immunother. 2002 Aug;51(6):320-6. Epub 2002 Jun 6.

PMID:
12111120
24.

M-Vax: an autologous, hapten-modified vaccine for human cancer.

Berd D.

Expert Opin Biol Ther. 2002 Mar;2(3):335-42.

PMID:
11890872
25.

Variability in glucose transporter-1 levels and hexokinase activity in human melanoma.

Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D, Leeper DB.

Melanoma Res. 2002 Feb;12(1):35-43.

PMID:
11828256
26.

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ.

Int J Cancer. 2001 Nov;94(4):531-9.

27.

Whole cell ELISA for detection of tumor antigen expression in tumor samples.

Erdile LF, Smith D, Berd D.

J Immunol Methods. 2001 Dec 1;258(1-2):47-53.

PMID:
11684122
28.

Autologous, hapten-modified vaccine as a treatment for human cancers.

Berd D.

Vaccine. 2001 Mar 21;19(17-19):2565-70. Review.

PMID:
11257393
29.

Protracted survival after resection of metastatic uveal melanoma.

Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T.

Cancer. 2000 Oct 1;89(7):1561-8.

PMID:
11013372
30.

Diagnostic dilemmas in oncology. Case 1. Melanoma metastatic to the testis.

Ejadi S, Rosenblum J, Berd D, McCue P, Mastrangelo M.

J Clin Oncol. 2000 Sep;18(17):3187-8. No abstract available.

PMID:
10963647
31.

Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.

Maguire HC Jr, Berd D, Lattime EC, McCue PA, Kim S, Chapman PB, Mastrangelo MJ.

Cancer Biother Radiopharm. 1998 Feb;13(1):13-23.

PMID:
10850338
32.

Melanoma vaccines as a therapeutic option.

Berd D.

South Med J. 2000 Apr;93(4):439-40. No abstract available.

PMID:
10798519
33.

Vulvar melanoma, biologically different from other cutaneous melanomas.

Dunton CJ, Berd D.

Lancet. 1999 Dec 11;354(9195):2013-4. No abstract available.

PMID:
10636360
34.

Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.

Nathan FE, Berd D, Sato T, Mastrangelo MJ.

Cancer. 2000 Jan 1;88(1):79-87.

PMID:
10618609
35.

Autologous, hapten-modified vaccine as a treatment for human cancers.

Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr.

Semin Oncol. 1998 Dec;25(6):646-53. Review.

PMID:
9865679
36.

Cancer vaccines: reborn or just recycled?

Berd D.

Semin Oncol. 1998 Dec;25(6):605-10. Review.

PMID:
9865675
37.

The Dartmouth Regimen: gone or going strong?

McClay EF, Berd D, Mastrangelo MJ.

Cancer Invest. 1998;16(6):421-3. Review. No abstract available.

PMID:
9679534
38.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

Sensi M, Farina C, Maccalli C, Anichini A, Berd D, Parmiani G.

J Immunother. 1998 May;21(3):198-204.

PMID:
9610911
39.

Cellular vaccine therapies for cancer.

Mastrangelo MJ, Sato T, Lattime EC, Maguire HC Jr, Berd D.

Cancer Treat Res. 1998;94:35-50. Review. No abstract available.

PMID:
9587681
40.

Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.

Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D.

Clin Immunol Immunopathol. 1997 Dec;85(3):265-72.

PMID:
9400626
41.

BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.

Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De Potter P, Mastrangelo MJ.

J Exp Clin Cancer Res. 1997 Jun;16(2):201-8.

PMID:
9261748
42.

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ.

J Clin Oncol. 1997 Jun;15(6):2359-70.

PMID:
9196151
43.

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D.

J Clin Invest. 1997 Feb 15;99(4):710-7.

44.

Active specific immunization in the treatment of patients with melanoma.

Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D.

Semin Oncol. 1996 Dec;23(6):773-81. Review.

PMID:
8970602
45.

Interleukin 10 production by human melanoma.

Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D.

Clin Cancer Res. 1996 Aug;2(8):1383-90.

46.

Melanoma and vitiligo: immunology's Grecian urn.

Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC Jr.

Cancer Immunol Immunother. 1996 Jun;42(5):263-7. Review. No abstract available.

PMID:
8706046
47.

Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.

Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli M-G, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K.

Int J Cancer. 1996 Mar 15;65(6):762-7.

48.

Gene therapy for human cancer: an essay for clinicians.

Mastrangelo MJ, Berd D, Nathan FE, Lattime EC.

Semin Oncol. 1996 Feb;23(1):4-21. Review.

PMID:
8607031
49.

Detection of specific genetic alterations in cancer cells.

Huebner K, Ohta M, Lubinski J, Berd D, Mag├╝ire HC Jr.

Semin Oncol. 1996 Feb;23(1):22-30. Review.

PMID:
8607029
50.

Human tumor vaccines go molecular. Summary of American Association for Cancer Research Symposium, March 20,1995.

Berd D, Parmiani G.

Cancer Immunol Immunother. 1995 Sep;41(3):199-200. No abstract available.

PMID:
7553690

Supplemental Content

Support Center